Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Renal Cell Cancer
Age: Between 18 - 100 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required